GLPwatch

After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?

Exp Clin Endocrinol Diabetes · 2016

Last updated 2026-05-28
JournalExp Clin Endocrinol Diabetes, 2016
Citations1
Relative citation ratio0.03
NIH percentile4
Molecules —
Conditions studied Type 2 Diabetes

Abstract

Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.

Verbatim abstract via PubMed 27701709 ↗